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Table S1. Mutagenesis strategies used for cloning of successfully expressed and produced IGF-1 and IGF-2 analogs.  
Analog (expression construct) Mutation(s) Forward mutagenic primer (5′-3′) Reverse mutagenic primer (5′-3′) Template construct Applied strategy 
Gly-1-IGF-1  -    
 
 























































IGF-2  -     













































Figure S1. Inhibition of binding of human [125I]monoiodotyrosyl-IGF-1 to human IGF-1R in 
mouse embryonic fibroblasts by Gly-1-IGF-1 (A), [His45]-IGF-1 (B), [Asn45]-IGF-1 (C), 
[Ala45]-IGF-1 (D), [His46]-IGF-1 (E), [Gln46]-IGF-1 (F), [Ala46]-IGF-1 (G), [Asn45,Gln46]-
IGF-1 (H) and by human IGF-1 (in all panels). All IGF-1 analogs have Gly at the position -1. The 






























Figure S1 (continued). Inhibition of binding of human [125I]monoiodotyrosyl-IGF-1 to human 
IGF-1R in mouse embryonic fibroblasts by [His49]-IGF-1 (I), [His46,His49]-IGF-1 (J), 
[Gln46,His49]-IGF-1 (K), [Asn45,Gln46,His49]-IGF-1 (L), human IGF-2 (M), [Gln45]-IGF-2 
(N), [His48]-IGF-2 (O), [Gln45,His48]-IGF-2 (P) and by human IGF-1 (in all panels). All IGF-1 






























Figure S2. Inhibition of binding of human [125I]monoiodotyrosyl-insulin to human IR-A in human 
IM-9 lymphocytes by Gly-1-IGF-1 (A), [His45]-IGF-1 (B), [Asn45]-IGF-1 (C), [Ala45]-IGF-1 
(D), [His46]-IGF-1 (E), [Gln46]-IGF-1 (F), [Ala46]-IGF-1 (G), [Asn45,Gln46]-IGF-1 (H) and by 
human insulin and human IGF-1 (in all panels). All IGF-1 analogs have Gly at the position -1. The 




























Figure S2 (continued). Inhibition of binding of human [125I]monoiodotyrosyl-insulin to human 
IR-A in human IM-9 lymphocytes by [His49]-IGF-1 (I), [His46,His49]-IGF-1 (J), [Gln46,His49]-
IGF-1 (K), [Asn45,Gln46,His49]-IGF-1 (L), human IGF-2 (M), [Gln45]-IGF-2 (N), [His48]-IGF-
2 (O), [Gln45,His48]-IGF-2 (P) and by human insulin (in all panels), human IGF-1  (in panels I-
L) and human IGF-2 (in panels M-P). All IGF-1 analogs have Gly at the position -1. The 




Figure S3. Inhibition of binding of human [125I]monoiodotyrosyl-insulin to human IR-B in mouse 
embryonic fibroblasts by human insulin, human IGF-1 and by [His49]-IGF-1 (in panel A), and by 
human insulin, human IGF-2 and by [Gln45,His48]-IGF-2 (in panel B). The representative binding 









Figure S4. A representative example of immunoblot used for evaluation of abilities of analogs to 







Figure S5. Representative dose response curves of the abilities of human IGF-1 and selected IGF-
1 analogs to stimulate autophosphorylation of IGF-1R. Stimulation by human IGF-1 is shown in 
panel A, by [His45]-IGF-1 in panel B, by [Asn45]-IGF-1 in panel C, by [Ala45]-IGF-1 in panel D, 
by [His46]-IGF-1 in panel E and by [Gln45]-IGF-1 in panel F. The EC50 values are shown in Table 
S2. 
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 Table S2. Comparison of abilities of selected IGF-1 analogs to activate IGF-1R in a dose response 
manner (EC50 values) with their ability to activate IGF-1R at 10 nM concentration.  
Analog Ability to activate 
autophosphorylation of 
IGF-1R  
EC50 ± S.D. [nM] (n) 




Relative activation of 
IGF-1R at 10 nM [%] 
± S.D. (n) 
human IGF-1 3.7 ± 0.7 (3) 100 ± 19 100 ± 13 (4) 
[His45]-IGF-1 5.4 ± 0.5 (3) 69 ± 6 71 ± 20 (4) 
[Asn45]-IGF-1 4.7 ± 0.8 (3) 79 ± 13 88 ± 18 (4) 
[Ala45]-IGF-1 3.1 ± 0.4 (3) 119 ± 15 80 ± 25 (4) 
[His46]-IGF-1 4.4 ± 0.6 (4) 84 ± 11 71 ± 11 (4) 
[Gln46]-IGF-1 4.4 ± 1.6 (3) 84 ± 30 69 ± 13 (4) 
a Relative ability to activate autophosphorylation of the receptor is defined as (EC50 of human 
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